An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2<sup>nd </sup>or higher line chemotherapy regarding clinical benefit - PANUSCO

<p>Abstract</p> <p>Background</p> <p>Pancreatic cancer is an extremely aggressive malignancy. Subjects are afflicted with a variety of disconcerting symptoms, including profound cachexia. Recent data indicate that the outcome of oncological patients suffering from cance...

Full description

Bibliographic Details
Main Authors: Rötzer Ingeborg, Büchler Markus W, Ose Jennifer, Wente Moritz N, Märten Angela, Decker-Baumann Christiane, Karapanagiotou-Schenkel Irini, Harig Sabine, Schmidt Jan, Jäger Dirk
Format: Article
Language:English
Published: BMC 2009-11-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/412